Posted by Michael Wonder on 11 Mar 2018
Is ICER NICEr?
21 February 2018 - Similar to NICE in the UK and the PBAC in Australia, the Institute for Clinical and Economic Review (ICER) is the first organisation in the US to address drug prices using cost-effectiveness methods, and to gain the attention of important stakeholders.
ICER is organised differently than NICE and PBAC; ICER is an independent, non-profit, non-governmental organisation that is funded by foundations to conduct evidence reviews on drugs that combine analyses of comparative clinical effectiveness and cost effectiveness in a way that produces recommendations for ‘value-based’ price benchmarks.
An ICER report is composed of six main parts: comparative clinical effectiveness, incremental cost effectiveness, potential benefits or disadvantages that lie outside the scope of clinical or cost effectiveness, contextual considerations, budget impact analysis, and a section in which the value-based price benchmark is calculated.
